hotspot -WSS

hotspot

author：focus 2025-08-23 08:56:16 - browse：911

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — A newly approved Alzheimer’s drug made by Eisai and Biogen, called Leqembi, aims to clear out amyloid plaques in patients’ brains. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

WASHINGTON — Medicare on Monday proposed ending restrictions on how many PET scans patients can receive to detect amyloid plaques in their brains, which will offer physicians more options as they treat patients with a new drug to slow the progression of dementia.

The agency that oversees Medicare had previously restricted coverage to a single scan for patients who participated in clinical studies. Advocates had warned that could cause issues related to a new class of Alzheimer’s drugs designed to clear those plaques.

“We know there is significant interest in the medical community about new treatments that may be effective in slowing the development of Alzheimer’s disease. PET scans are an important part of diagnosis and treatment of Alzheimer’s disease,” Centers for Medicare and Medicaid Administrator Chiquita Brooks-LaSure said in a written statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Medical mystery: When a cough is not just a cough

WSS

How clinical AI models' predictive power can degrade over time

KalVista pill reduced swelling 'attacks' caused by genetic disease

There’s no way to know how good AI health technologies are

European regulators recommend Amylyx's ALS drug be rejected

European regulators recommend Amylyx's ALS drug be rejected

What we’ve learned from the Aduhelm mess

Wikipedia

hotspot

hotspot

Sports medicine is finally prioritizing gender equality

Senators start work on Medicare physician payment reform

Activists slam private health insurers over coverage restrictions

The dental labor crisis is a moment of opportunity

Affirmative action in medical school literally saved lives

STAT Readout: Today's biotech news includes Sana and Amylyx

Continuity nursing helped my family in our darkest PICU moments

What's changing in Medicare's open enrollment this year?

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

KalVista pill reduced swelling 'attacks' caused by genetic disease

leisure time

'Revelatory' study finds a smoking impact that remains after quitting

How digital tools helped lower hypertension in marginalized patients

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Peter Marks talks Operation Warp Speed for Rare Diseases

Industry veterans launch new biotech VC with $310M

'Revelatory' study finds a smoking impact that remains after quitting

focus

hotspot

explore

leisure time